AbbVie: Competitor Pricing, Humira Formulary Placement Will Dictate US Biosimilars Impact
Executive Summary
Now just months away from the first US Humira biosimilar launch, analysts are asking AbbVie for specifics on expected revenue erosion. CEO Gonzalez said AbbVie aims for 90% formulary coverage in 2023.